MICHAEL ITTMANN to Neoplasm Staging
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Neoplasm Staging.
Connection Strength
0.102
-
Genomic profiling of prostate cancers from African American men. Neoplasia. 2009 Mar; 11(3):305-12.
Score: 0.029
-
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res. 1998 Mar; 4(3):811-5.
Score: 0.013
-
Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Prostate. 1996 May; 28(5):275-81.
Score: 0.012
-
Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol. 1996 Jan; 27(1):28-34.
Score: 0.012
-
Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol. 1994 Aug; 145(2):287-93.
Score: 0.010
-
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn. 2013 Mar; 15(2):270-9.
Score: 0.009
-
Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
Score: 0.008
-
Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001 May 15; 61(10):3882-5.
Score: 0.004
-
Androgen receptor mutations in prostate cancer. Cancer Res. 2000 Feb 15; 60(4):944-9.
Score: 0.004